Aytu BioPharma Inc

NASDAQ:AYTU  
1.20
-0.06 (-4.76%)
Products

Denovo Biopharma Llc Announces Partner Aytu Biopharma Receives FDA Clearance For Enzastaurin

Published: 12/14/2021 17:51 GMT
Aytu BioPharma Inc (AYTU) - Denovo Biopharma Llc Announces Partner Aytu Biopharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-danlos Syndrome.
Denovo Biopharma- Aytu Plans to Initiate Prevent Trial in Veds in First Half of 2022.